

---

# INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES

(p-ISSN: 2348-5213; e-ISSN: 2348-5221)

[www.ijcreps.com](http://www.ijcreps.com)

(A Peer Reviewed, Referred, Indexed and Open Access Journal)

DOI: 10.22192/ijcreps

Coden: IJCROO(USA)

Volume 11, Issue 5- 2024

---

## Review Article



DOI: <http://dx.doi.org/10.22192/ijcreps.2024.11.05.003>

## Update on Hematopoietic Growth Factors in Aplastic Anemia with HIV

**\*Emmanuel Ifeanyi Obeagu<sup>1</sup> and Teddy Charles Adias<sup>2</sup>**

<sup>1</sup>Department of Medical Laboratory Science, Kampala International University, Uganda.

<sup>2</sup>Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science, Federal University Otuoke, Bayelsa State, Nigeria

ORCID: 0000-0001-7057

\*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, [emmanuelobeagu@yahoo.com](mailto:emmanuelobeagu@yahoo.com),

ORCID: 0000-0002-4538-0161

---

### Abstract

Aplastic anemia (AA) and HIV represent a challenging intersection of hematologic and infectious diseases, significantly complicating diagnosis and treatment. Hematopoietic growth factors (HGFs), including granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoiesis-stimulating agents (ESAs), have become essential in managing AA, especially in immunocompromised patients. This review provides an update on the role of HGFs in treating AA among HIV-infected patients, focusing on their efficacy, safety, and emerging therapeutic strategies. G-CSF has shown substantial efficacy in reducing infection rates and improving neutrophil counts in HIV-infected patients with AA, although careful monitoring is necessary to manage potential side effects. GM-CSF, with its broader action on early progenitor cells, has also demonstrated benefits in enhancing myeloid recovery, albeit with a higher incidence of adverse effects like fever and fluid retention. ESAs play a critical role in managing anemia in these patients, reducing the need for transfusions and improving quality of life when used alongside antiretroviral therapy (ART). Recent advances have opened new avenues for integrating HGFs with other treatments, such as immunosuppressive therapy (IST) and stem cell transplantation, which offer potential cures but come with significant risks for HIV-infected patients. Ongoing research aims to optimize the use of HGFs in combination with ART and supportive care, promising better outcomes for this complex and vulnerable patient population.

**Keywords:** Aplastic anemia, HIV, Hematopoietic growth factors, G-CSF, GM-CSF, Erythropoiesis-stimulating agents, Bone marrow failure

---

## Introduction

Aplastic anemia (AA) is a rare but life-threatening condition characterized by pancytopenia and a hypocellular bone marrow, leading to severe deficits in red blood cells, white blood cells, and platelets. The etiology of AA can be diverse, including autoimmune destruction of hematopoietic stem cells, exposure to certain drugs or chemicals, viral infections, and inherited bone marrow failure syndromes. The disease manifests clinically with symptoms such as fatigue, recurrent infections, and bleeding tendencies, reflecting the underlying marrow failure.<sup>1-2</sup> The coexistence of AA and HIV infection presents a particularly challenging clinical scenario. HIV, the virus responsible for acquired immunodeficiency syndrome (AIDS), directly affects the immune system by targeting CD4+ T cells, leading to progressive immunosuppression. This immunocompromised state not only predisposes individuals to opportunistic infections and malignancies but also complicates the management of comorbid conditions like AA. HIV can directly invade hematopoietic progenitor cells and the bone marrow microenvironment, exacerbating the hematologic abnormalities.<sup>3-5</sup>

Hematopoietic growth factors (HGFs) have revolutionized the treatment landscape for various hematologic conditions by promoting the proliferation and differentiation of blood cells. In the context of AA, HGFs such as granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and erythropoiesis-stimulating agents (ESAs) have been pivotal in improving hematologic outcomes. These agents are particularly valuable in managing the cytopenias associated with AA, thereby reducing infection rates, transfusion requirements, and enhancing overall patient survival.<sup>6-7</sup> The interplay between HIV and AA necessitates a nuanced understanding of the pathophysiology underlying bone marrow failure in these patients. HIV-associated bone marrow suppression can result from multiple mechanisms, including direct viral infection of marrow cells, immune-mediated marrow destruction, and the

effects of ART or other medications. The compounded marrow suppression in HIV-infected individuals with AA underscores the critical role of HGFs in their management.<sup>8-9</sup> Granulocyte colony-stimulating factor (G-CSF) is commonly used to address neutropenia, a condition of low neutrophil counts, which increases the risk of infections. G-CSF stimulates the production and release of neutrophils from the bone marrow, enhancing the immune defense in neutropenic patients. In HIV-infected patients with AA, G-CSF has been shown to effectively increase neutrophil counts and reduce infection rates, although its use must be carefully monitored to avoid adverse effects such as splenomegaly and bone pain.<sup>10-11</sup>

Granulocyte-macrophage colony-stimulating factor (GM-CSF) acts on a broader spectrum of progenitor cells compared to G-CSF, promoting the proliferation of granulocytes and macrophages. This broader action makes GM-CSF a valuable agent in enhancing myeloid recovery in AA patients. However, its use in HIV-infected patients is associated with a higher incidence of side effects, including fever and fluid retention, necessitating careful patient selection and monitoring.<sup>12-13</sup> Erythropoiesis-stimulating agents (ESAs) like erythropoietin and darbepoetin are integral in managing anemia in patients with AA and HIV. ESAs stimulate red blood cell production, reducing the need for frequent transfusions and improving the quality of life. In HIV-infected patients, the combination of ESAs with ART requires careful management to address potential drug interactions and optimize the erythropoietic response, thereby minimizing anemia-related complications.<sup>14-15</sup>

## Pathophysiology of Aplastic Anemia in HIV

Aplastic anemia (AA) in HIV-infected individuals represents a complex interplay between the virus, immune response, and bone marrow function. Understanding the pathophysiology requires examining how HIV affects hematopoiesis directly and indirectly, as well as the impact of HIV-related treatments and opportunistic infections. HIV can directly infect bone marrow

stromal cells, which are crucial for supporting hematopoiesis. This infection disrupts the bone marrow microenvironment, impairing the ability of stromal cells to support the growth and differentiation of hematopoietic progenitor cells.<sup>16-18</sup> While less common, HIV can also directly infect CD34+ hematopoietic progenitor cells. This direct infection can lead to apoptosis (programmed cell death) of these progenitor cells, further depleting the bone marrow's ability to produce new blood cells. HIV infection leads to significant immune dysregulation, characterized by both immunosuppression and chronic immune activation. Increased levels of cytokines such as tumor necrosis factor-alpha (TNF- $\alpha$ ), interferon-gamma (IFN- $\gamma$ ), and interleukin-1 (IL-1) can inhibit hematopoiesis. These cytokines can induce apoptosis in hematopoietic progenitor cells and suppress their proliferation. HIV infection may trigger autoimmune responses, leading to the production of autoantibodies against hematopoietic cells. The immune system may attack and destroy bone marrow cells, contributing to pancytopenia.<sup>19-21</sup>

Certain antiretroviral drugs, especially older nucleoside reverse transcriptase inhibitors (NRTIs) like zidovudine (AZT), can be toxic to bone marrow cells. Drug-induced bone marrow suppression can lead to anemia, neutropenia, and thrombocytopenia. Some ART drugs cause mitochondrial dysfunction in bone marrow cells, leading to impaired cellular energy metabolism. This can result in increased apoptosis and reduced proliferation of hematopoietic progenitor cells. Parvovirus B19 specifically targets erythroid progenitor cells in the bone marrow. Infection can lead to pure red cell aplasia, a condition marked by severe anemia due to the destruction of red blood cell precursors. **Mycobacterium avium Complex (MAC)** can infiltrate the bone marrow, causing granulomatous inflammation. This infiltration disrupts normal bone marrow architecture and function, contributing to pancytopenia. **Cytomegalovirus (CMV)** can infect bone marrow stromal and progenitor cells. CMV infection leads to bone marrow suppression and can exacerbate cytopenias in HIV-infected individuals.<sup>22-23</sup>

## Role of Hematopoietic Growth Factors

Hematopoietic growth factors (HGFs) play a crucial role in managing aplastic anemia (AA) in individuals with HIV. These factors help stimulate the production of various blood cell lineages, addressing the pancytopenia that characterizes AA. Here, we discuss the roles and applications of key HGFs, including granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoiesis-stimulating agents (ESAs), and thrombopoietin (TPO) receptor agonists.<sup>24</sup>

### Granulocyte Colony-Stimulating Factor (G-CSF)

G-CSF stimulates the proliferation and differentiation of neutrophil precursors in the bone marrow. It enhances the function and survival of mature neutrophils. G-CSF is primarily used to treat neutropenia in HIV patients, reducing the risk of infections. Studies have shown that G-CSF can effectively increase neutrophil counts in HIV-infected patients with AA, leading to fewer infections and hospitalization days. G-CSF is generally well-tolerated, with common side effects including bone pain, splenomegaly, and, rarely, splenic rupture. Long-term use requires monitoring for potential complications such as leukocytosis and bone marrow exhaustion.<sup>25</sup>

### Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)

GM-CSF stimulates the production of granulocytes (neutrophils, eosinophils, and basophils) and macrophages from progenitor cells. It enhances the function of mature myeloid cells, improving phagocytosis and antigen presentation. GM-CSF is used less frequently than G-CSF but can be beneficial in cases where broader stimulation of the myeloid lineage is needed. GM-CSF may support overall immune recovery in HIV patients by enhancing macrophage function. Side effects include fever, bone pain, and injection site reactions. There is a potential risk of exacerbating inflammatory

conditions due to its broader immunostimulatory effects.<sup>26</sup>

### **Erythropoiesis-Stimulating Agents (ESAs)**

ESAs, such as epoetin alfa and darbepoetin alfa, stimulate the production of red blood cells by mimicking the action of endogenous erythropoietin. They act on erythroid progenitor cells in the bone marrow, promoting their proliferation and differentiation. ESAs are used to treat anemia in HIV patients, especially those on zidovudine-based antiretroviral therapy, which is known to cause anemia. By increasing hemoglobin levels, ESAs reduce the need for blood transfusions and improve patients' quality of life. Risks include hypertension, thromboembolic events, and pure red cell aplasia. Regular monitoring of hemoglobin levels is necessary to avoid excessive erythropoiesis and associated complications.<sup>27</sup>

### **Thrombopoietin (TPO) Receptor Agonists**

TPO receptor agonists, such as eltrombopag and romiplostim, stimulate the production of platelets by activating the thrombopoietin receptor on megakaryocytes and their progenitors. These agents are used to treat thrombocytopenia, increasing platelet counts and reducing bleeding risks in HIV patients with AA. They are particularly useful in patients who have not responded adequately to other treatments. Common side effects include headache, fatigue, and nausea. There is a potential risk of hepatotoxicity and thromboembolic events, necessitating regular liver function and platelet count monitoring.<sup>27</sup>

### **Combined and Sequential Use of HGFs**

In the context of AA with HIV, the combined and sequential use of HGFs can be tailored to the patient's specific hematologic deficits and response to treatment. For instance, G-CSF can be used initially to address neutropenia, followed by ESAs to manage anemia. Thrombopoietin receptor agonists can be added if thrombocytopenia persists.<sup>28</sup>

## **Emerging Therapies and Future Directions**

The management of aplastic anemia (AA) in the context of HIV remains challenging due to the complex interplay between the virus, immune dysregulation, and bone marrow failure. While hematopoietic growth factors (HGFs) have improved outcomes, emerging therapies and novel approaches offer the potential for more effective and targeted treatments. This section explores the latest advancements and future directions in the treatment of AA with HIV.<sup>29</sup>

### **Gene Therapy**

#### **1. CRISPR-Cas9 Gene Editing:**

CRISPR-Cas9 technology allows for precise editing of genetic mutations associated with AA. Researchers are exploring the use of CRISPR to correct mutations in hematopoietic stem cells (HSCs), potentially restoring normal hematopoiesis. Ensuring targeted and safe gene editing, avoiding off-target effects, and achieving efficient delivery of the gene-editing components to HSCs.<sup>30</sup>

#### **2. Lentiviral Vector-Mediated Gene Therapy:**

Lentiviral vectors are used to deliver corrective genes to HSCs. This approach has shown promise in preclinical models for treating genetic forms of AA and may be adapted for HIV-related cases. Overcoming immune rejection and ensuring long-term expression of the therapeutic gene.

### **Stem Cell Transplantation**

#### **1. Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)**

Transplantation of HSCs from a healthy donor to replace the defective bone marrow. HSCT remains a potential curative option for AA. In HIV patients, this approach is complicated by the risk of opportunistic infections and graft-versus-host disease (GVHD). Finding suitable donors, managing immunosuppression, and ensuring HIV control during and after transplantation.<sup>29</sup>

## 2. Autologous HSCT with Gene Therapy

Patients' own HSCs are harvested, genetically modified to correct defects, and then reinfused. This approach reduces the risk of GVHD and immunological complications. Efficiently modifying HSCs and achieving durable engraftment and hematopoietic recovery.<sup>28</sup>

## Immune Modulation

### 1. Anti-Inflammatory Therapies

Targeting inflammatory cytokines and immune pathways that contribute to bone marrow suppression. Agents such as TNF- inhibitors and JAK inhibitors are being investigated for their potential to reduce inflammation and support hematopoiesis. Balancing immunosuppression with the risk of infections, particularly in HIV-infected individuals.<sup>15</sup>

### 2. Regulatory T Cell (Treg) Therapy

Enhancing the function or numbers of Tregs to modulate immune responses and reduce autoimmunity in AA. Treg therapy could help restore immune tolerance and improve bone marrow function. Developing methods to expand and deliver functional Tregs effectively.

## Novel Hematopoietic Growth Factors

### 1. Long-Acting Growth Factors

Modified HGFs with extended half-lives to reduce the frequency of administration. These agents could improve patient adherence and reduce healthcare burden. Ensuring safety and efficacy in HIV-infected individuals.

### 2. Combination Therapies

Using combinations of HGFs to synergistically stimulate multiple hematopoietic lineages. Combination therapies could address pancytopenia more effectively than single agents. Managing potential additive side effects and determining optimal dosing regimens.

## Targeted Therapies

### 1. Small Molecule Inhibitors:

Targeting specific pathways involved in bone marrow failure and immune dysregulation. Agents such as TGF- inhibitors and Notch pathway modulators are being explored for their potential to enhance hematopoiesis. Identifying appropriate targets and minimizing off-target effects.

### 2. Epigenetic Modulators:

Modulating gene expression through epigenetic changes to enhance hematopoiesis. Drugs such as DNA methyltransferase inhibitors and histone deacetylase inhibitors are under investigation. Understanding the epigenetic landscape of AA and HIV, and ensuring targeted effects.

## Conclusion

The management of aplastic anemia (AA) in HIV-infected individuals presents a unique and complex challenge due to the multifaceted interplay between HIV infection, immune dysregulation, and bone marrow failure. Traditional approaches, including the use of hematopoietic growth factors (HGFs) such as G-CSF, GM-CSF, erythropoiesis-stimulating agents (ESAs), and thrombopoietin receptor agonists, have significantly improved patient outcomes by addressing specific hematologic deficiencies and reducing complications like infections and transfusion dependency. Emerging therapies offer new hope for more effective and targeted treatments. Gene therapy, particularly using CRISPR-Cas9 and lentiviral vectors, holds potential for correcting genetic defects and restoring normal hematopoiesis. Stem cell transplantation, both allogeneic and autologous with gene therapy, remains a potential curative option, although it comes with challenges such as graft-versus-host disease and immunosuppression. Immune modulation strategies, including anti-inflammatory therapies and regulatory T cell therapy, aim to mitigate immune-mediated bone marrow suppression, offering another avenue for


improving bone marrow function. Novel HGFs with extended half-lives and combination therapies promise to enhance patient adherence and efficacy in treating pancytopenia. Additionally, targeted therapies, such as small molecule inhibitors and epigenetic modulators, are being explored to address specific pathways involved in bone marrow failure and immune dysregulation.

## References

1. Boddu PC, Kadia TM. Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review. *Expert review of hematology*. 2017;10(5):433-448.
2. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review*. *Newport International Journal of Public Health and Pharmacy (Nijpp)*. 2023;3(2):64-67.
3. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV infection and cardiovascular diseases: the obnoxious duos. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
4. Obeagu EI, Obeagu GU. The Role of Blood Transfusion Strategies in HIV Management: Current Insights and Future Directions. *Elite Journal of Medicine*, 2024; 2(1):10-22
5. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. *Asian J Dental Health Sci*. 2024; 30];3(2):7-14.  
<http://ajdhs.com/index.php/journal/article/view/39>
6. Ivanov AV, Valuev-Elliston VT, Ivanova ON, Kochetkov SN, Starodubova ES, Bartosch B, Isaguliant MG. Oxidative stress during HIV infection: mechanisms and consequences. *Oxidative medicine and cellular longevity*. 2016;2016.
7. González-Blanco I, Calás-Hechavarria V, Gravier-Hernández R, Pérez-Correa D, Reyes-Pérez A, Hernández-Requejo D, Guevara-García M, García-Mir V, Gil-del Valle L, León-Fernández OS, Pérez-Ávila LJ. Oxidant/antioxidant status in subjects with HIV infection in different clinical conditions. *Biomedicine & Aging Pathology*. 2014;4(3):235-242.
8. Salmen S, Berrueta L. Immune modulators of HIV infection: the role of reactive oxygen species. *J Clin Cell Immunol*. 2012;3(121):2.
9. Obeagu EI, Obeagu GU. Transfusion-Related Complications in Children Under 5 with Coexisting HIV and Severe Malaria: A Review. *Int. J. Curr. Res. Chem. Pharm. Sci*. 2024;11(2):9-19.
10. Zicari S, Sessa L, Cotugno N, Ruggiero A, Morrocchi E, Concato C, Rocca S, Zangari P, Manno EC, Palma P. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. *Viruses*. 2019;11(3):200.
11. Obeagu EI, Anyiam AF, Obeagu GU. Managing Anemia in HIV through Blood Transfusions: Clinical Considerations and Innovations. *Elite Journal of HIV*, 2024; 2(1): 16-30
12. Sharma B. Oxidative stress in HIV patients receiving antiretroviral therapy. *Current HIV research*. 2014;12(1):13-21.
13. Mathys L, Balzarini J. The role of cellular oxidoreductases in viral entry and virus infection-associated oxidative stress: potential therapeutic applications. *Expert opinion on therapeutic targets*. 2016;20(1):123-143.
14. Zhao XC, Ju B, Xiu NN, Sun XY, Meng FJ. When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms. *Frontiers in Immunology*. 2024; 15:1339971.

15. Obeagu EI. Immunological Insights into Aplastic Anemia within the Context of HIV: Unraveling the Complex Interplay. *Elite Journal of Health Science*. 2023;1(1):14-24.
16. Obeagu EI, Obeagu GU. GATA-1 and Hematopoietic Stem Cell Quiescence in HIV: Implications for Therapy. *Elite Journal of Medicine*. 2024;2(4):19-36.
17. Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
18. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
19. Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. [links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf](https://doi.org/10.21960/jphn.v6i2.141).
20. Sezaki M, Hayashi Y, Wang Y, Johansson A, Umemoto T, Takizawa H. Immunomodulation of hematopoietic stem and progenitor cells in inflammation. *Frontiers in immunology*. 2020; 11:585367.
21. Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38. DOI: [10.22192/ijcrms.2017.03.01.004](https://doi.org/10.22192/ijcrms.2017.03.01.004)
22. Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. [links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf](https://doi.org/10.21960/jphn.v5i6.129).
23. Jahandideh B, Derakhshani M, Abbaszadeh H, Movassaghpour AA, Mehdizadeh A, Talebi M, Yousefi M. The pro-Inflammatory cytokines effects on mobilization, self-renewal and differentiation of hematopoietic stem cells. *Human Immunology*. 2020;81(5):206-217.
24. Cribbs SK, Crothers K, Morris A. Pathogenesis of HIV-related lung disease: immunity, infection, and inflammation. *Physiological reviews*. 2020;100(2):603-632.
25. Zhao XC, Ju B, Xiu NN, Sun XY, Meng FJ. When inflammatory stressors dramatically change, disease phenotypes may transform between autoimmune hematopoietic failure and myeloid neoplasms. *Frontiers in Immunology*. 2024; 15:1339971.
26. Safe IP, Amaral EP, Araujo-Pereira M, Lacerda MV, Printes VS, Souza AB, Beraldi-Magalhaes F, Monteiro WM, Sampaio VS, Barreto-Duarte B, Andrade AM. Adjunct N-acetylcysteine treatment in hospitalized patients with HIV-associated tuberculosis dampens the oxidative stress in peripheral blood: Results from the RIPENACTB study trial. *Frontiers in immunology*. 2021; 11:602589.
27. Iriart X, Le Bouar M, Kamar N, Berry A. Pneumocystis pneumonia in solid-organ transplant recipients. *Journal of Fungi*. 2015;1(3):293-331.
28. Adias TC, Erhabor O. Human Immunodeficiency Virus Testing Algorithm in Resource Limiting Settings. In *Current Perspectives in HIV Infection 2013*: 480. Rijeka: InTech.

29. Jeremiah ZA, Obazee Y, Okogun GR, Adias TC, Mgbere O, Essien EJ. Impact of short-term antiretroviral therapy (START) on some fibrinolytic markers in HIV-infected Nigerian adults: preliminary findings from the START study. *HIV/AIDS-Research and Palliative Care*. 2012;87-94.
30. Daniel-Moreno A, Lamsfus-Calle A, Raju J, Antony JS, Handgretinger R, Mezger M. CRISPR/Cas9-modified hematopoietic stem cells—present and future perspectives for stem cell transplantation. *Bone Marrow Transplantation*. 2019;54(12):1940-1950.

Access this Article in Online	
	Website: <a href="http://www.ijcrcps.com">www.ijcrcps.com</a>
	Subject: Hematology
Quick Response Code	
DOI: <a href="https://doi.org/10.22192/ijcrcps.2024.11.05.003">10.22192/ijcrcps.2024.11.05.003</a>	

How to cite this article:

Emmanuel Ifeanyi Obeagu and Teddy Charles Adias. (2024). Update on Hematopoietic Growth Factors in Aplastic Anemia with HIV. *Int. J. Curr. Res. Chem. Pharm. Sci.* 11(5): 23-30.  
DOI: <http://dx.doi.org/10.22192/ijcrcps.2024.11.05.003>